Browsing Tag
AMTAGVI
3 posts
Replimune Group (NASDAQ: REPL) plans layoffs after FDA rejects Tudriqev again, forcing a biotech reset
Replimune plans layoffs after the FDA rejected Tudriqev again. Read what the setback means for REPL stock, cash runway, strategy, and rivals.
Why Iovance Biotherapeutics faces a class action lawsuit after a 45% stock crash
Iovance faces a class action lawsuit after cutting 2025 revenue guidance by 40%. Learn what triggered the stock’s 45% drop and how investors can file claims.
FDA approves Iovance’s AMTAGVI: A breakthrough in melanoma treatment
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a trailblazer in the field of biotechnology focused on developing novel polyclonal tumor…